Liver Fibrosis clinical trials

Explore recruiting liver fibrosis clinical trials.

Recruiting liver fibrosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Liver Fibrosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Effects of NNC0194-0499 alone and in combination with semaglutide, of semaglutide alone, and of cagrilintide alone and in combination with semaglutide on liver damage and alcohol use in people with alcohol-related liver disease

Germany, Greece, Bulgaria, France, Denmark, Czechia +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Effect of Mediterranean diet combined with intermittent fasting on liver fibrosis compared to naltrexone/bupropion (Mysimba) in people with cardiometabolic risk factors

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Efficacy of simvastatin reducing liver fibrosis in patients with advanced fibrosis due to alcohol: a randomized, double-blind, placebo-controlled clinical trial.

Spain

Phase II and Phase III (Integrated) EU CTIS Study details

Randomized, double-blind, placebo-controlled study on the efficacy and safety of nicotinamide in patients with liver fibrosis.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis

Spain, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis

Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Liver Fibrosis trials by city

Liver Fibrosis in Toronto Liver Fibrosis in Vancouver Liver Fibrosis in Montreal Liver Fibrosis in Calgary Liver Fibrosis in Edmonton Liver Fibrosis in Ottawa Liver Fibrosis in Winnipeg Liver Fibrosis in Quebec City Liver Fibrosis in Hamilton Liver Fibrosis in Kitchener Liver Fibrosis in London Liver Fibrosis in Halifax Liver Fibrosis in New York Liver Fibrosis in Los Angeles Liver Fibrosis in Chicago Liver Fibrosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease